EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore

Elaine Hsuen Lim, Andrew Lim, Jasmeet Singh Khara, John Cheong, Jek Fong, Sivabalan Sivanesan, Matt Griffiths, Emma New, Soo Chin Lee

Expert Review of Pharmacoeconomics & Outcomes Research · 2024

DOI: 10.1080/14737167.2023.2295474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Elaine Hsuen Lim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Breast Neoplasms, Biosimilar Pharmaceuticals, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche Singapore Pte Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The Asian PEONY trial showed that add-on pertuzumab to trastuzumab and chemotherapy significantly improved pathological complete response in the neoadjuvant treatment of patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC). This study evaluated the cost-effectiveness of pertuzumab as an add-on therapy to trastuzumab and chemotherapy for neoadjuvant treatment of patients with HER2+ EBC in Singapore. METHODS: A six-state Markov model was developed from the Singapore healthcare system perspective, with a lifetime time horizon. Model outputs were: costs; life-years (LYs); quality-adjusted LYs (QALYs); incremental cost-effectiveness ratios (ICERs). Sensitivity/scenario analyses explored model uncertainties. RESULTS: The base case projected the addition of pertuzumab to be associated with improved outcomes by 0.277 LYs and 0.271 QALYs, increased costs by S$1,387, and an ICER of S$5,121/QALY. The ICER was most sensitive to the pCR rate, and the probabilistic sensitivity analysis showed that add-on pertuzumab had an 81.3% probability of being cost-effective at a willingness-to-pay threshold of S$45,000/QALY gained. CONCLUSIONS: This model demonstrated that the long-term clinical impact of early pertuzumab use, particularly the avoidance of metastatic disease and thus avoidance of higher costs and mortality rates, make neoadjuvant pertuzumab a cost-effective option in the management of patients with HER2+ breast cancer in Singapore.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBiosimilar PharmaceuticalsAntibodies, Monoclonal, HumanizedHumansFemaleNeoadjuvant TherapyCost-Effectiveness AnalysisSingaporeErb-b2 Receptor Tyrosine KinasesCost-Benefit AnalysisAntineoplastic Combined Chemotherapy ProtocolsTrastuzumab

Stichwörter der Autor:innen

Cost effectivenessHER2Singaporeearly breast cancerneoadjuvantpertuzumab

Substanzen

Biosimilar PharmaceuticalsErb-b2 Receptor Tyrosine KinasesTrastuzumabAntibodies, Monoclonal, Humanizedpertuzumab

Autor:innen und Institutionen

  • Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Asia-Pacific Evidence Development, Costello Medical Singapore Pte Ltd, Singapore, Singapore.
  • Medical, Roche Singapore Pte Ltd, Singapore, Singapore.
  • Market Access, Roche Singapore Pte Ltd, Singapore, Singapore.
  • HTA, Costello Medical Consulting Ltd, London, UK.
  • Health Economics, Costello Medical Consulting Ltd, London, UK.

Förderung

  • Roche Singapore Pte Ltd

Zitieren

APA

Lim, E. H., Lim, A., Khara, J. S., Cheong, J., Fong, J., Sivanesan, S., Griffiths, M., New, E., & Lee, S. C. (2024). Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2023.2295474

Vancouver

Lim EH, Lim A, Khara JS, Cheong J, Fong J, Sivanesan S, et al. Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2023.2295474

BibTeX
@article{Lim2024,
  author = {Lim, Elaine Hsuen and Lim, Andrew and Khara, Jasmeet Singh and Cheong, John and Fong, Jek and Sivanesan, Sivabalan and Griffiths, Matt and New, Emma and Lee, Soo Chin},
  title = {Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2024},
  doi = {10.1080/14737167.2023.2295474}
}
Kostenlos starten →